PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application

MICHAEL VALENTINE AGREZ, ET AL.

Application No.

10/019,816

Filed

December 28, 2001

For

A METHOD OF MODULATING INTEGRIN MEDIATED

CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME

Examiner

:

Attorney's Docket

SW-046XX

Group Art Unit:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

By:

Charles L. Gagnebin III Registration No. 25,467 Attorney for Applicant(s)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

It is desired to cite for the record in this application the enclosed references listed on the attached copy of PTO Form #1449. The paragraph(s) marked below are applicable to this Information Disclosure Statement.

(1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached [X]Information Disclosure Statement is being filed within three months of the filing date of the above identified national application or within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 of the above identified application. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.

Express Mail Number

EV 009950073 US

WEINGARTEN SCHURGIN GAGNEBIN & LEBOVICI LLP TEL. 617 540 2290 FAX: 617 451 0313

Applinion No.: 10/019,816 Filed: December 28, 2001 Group Art Unit:

- [] (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [] (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [] (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
 - [] a statement under 37 CFR § 1.97(e); or
 - [] the fee set forth in § 1.17(p).

PETITION UNDER 37 CFR § 1.97(d)

[] (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(p).

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

[] (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(2)

[] (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the attached Information Disclosure

ion No.: 10/019,816 Filed: December 28, 2001 Group Art Unit:

Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

These references were cited in an International Search Report (copy enclosed) which issued in International Application No. PCT/AU00/00729 filed June 28, 2000.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,

MICHAEL VALENTINE AGREZ, ET AL.

By:

charles L. Gagrebin III Registration No. 25,467 Attorney for Applicant(s)

WEINGARTEN, SCHURGIN, GAGNEBIN & LEBOVICI LLP Ten Post Office Square Boston, Massachusetts 02109 Telephone: (617) 542-2290

Telecopier: (617) 451-0313

Date: 3-97-2

CLG: kmw/264536-1

Enclosure

Date: March 27, 2002 Page 2 of 2

Form PTO-144 (REV. 07/01)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. SW-046XX		APPLICATION NO. 10/019,816		
(NE 1. 0//01)	PATENT AND TRADEMAN								
	INFORMATION DISCLOSUR	E CITATION							
(Use several sheets if necessary)									
(coc core and succession y necession y)				APPLICANT:					
				Michael Valentine Agrez, et al.					
				FILING DATE			GROUP		
				December 28, 2001		S.KOO!			
		U.S. PATI	ENT DOCUMENT	<u> </u>		1.			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE NAME		ME	CLASS	ASS SUBCLASS	FILING DATE IF APPROPRIATE*		
							 		
			+		 				
					<u> </u>				
	T		ATENT DOCUME		- - - - - - - - - - 	Г	т		
	DOCUMENT NUMBER	DATE	COUN	COUNTRY		SUBCLASS TRANSLATIO YES NO			
	WO 92/12236	7/23/1992	PCT				X		
							F		
								1	
			+						
	OTHER DOCL	MENTS (including	Title De	. D					
	The Journal of Biological Chemi Integrin β Subunit (β ₆) Identified	istry, Vol. 265, N	ing Author, Title, Da. No. 20, 1990, Shep ells Using the Poly	ppard, et al., "	Complete A	mino Acid Sec pp. 11502-115	quence of	a Novel	
	Cell Growth and Differentiation, Vol. 8, 1997, Gotoh, et al., "Cross-Linking of Integrins Induces Tyrosine Phosphorylation of the Proto-Oncogene Product Vav and the Protein Tyrosine Kinase Syk in Human Factor-dependent Myeloid Cells", pp. 721-729								
	The Journal of Cell Biology, Vol. 136, No. 6, 1997, Lin, et al., "Integrin-mediated Activation of MAP Kinase is Independent of FAK: Evidence for Dual Integrin Signaling Pathways in Fibroblasts", pp. 1385-1395								
	The International Journal of Biochemistry & Cell Biology, Vol. 32, 2000, Coppolino and Dedhar, "Bi-directional signal transduction by integrin receptors", pp. 171-188								
EXAMINER	DATE CONSIDERED								
EXAMINER: 1	Initial if citation considered, whether or n	not citation is in ce	onformance with MI	PEP 609; Draw	line through	citation if not in	conforman	ce and	
iot considered. In	nclude copy of this form with next comm	nunication to appli	icant.		-				